SİBEL ZEHRA AYDIN, GEZMİŞ KİMYON, CEM ÖZİŞLER, EMİNE FİGEN TARHAN, ESEN KASAPOĞLU GÜNAL, ADEM KÜÇÜK, AHMET OMMA, DİLEK SOLMAZ, EMİNE DUYGU ERSÖZLÜ, FATİH YILDIZ, MÜGE AYDIN TUFAN, MUHAMMET ÇINAR, RIDVAN MERCAN, ŞULE YAVUZ, FATIMA ARSLAN ALHUSSAİN, ABDULSAMET ERDEN, MERYEM CAN, GÖZDE YILDIRIM ÇETİN, LEVENT KILIÇ, SİBEL BAKIRCI, NOURA AL OSAİMİ, UMUT KALYONCU
European Journal of Rheumatology - 2020;7(2):64-67
Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology. Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA). Correlations between PSI, BSA, and other patient- and physician- reported outcomes were investigated. Results: There was a good correlation between PSI and BSA (r=0.546, p<0.001), which was even higher for mild psoriasis (BSA<3 (n=164): r=0.608, p<0.001). PSI significantly correlated with fatigue, pain, and patient and physician global parameters (p<0.001). Conclusion: PSI has a good correlation with other patient- and physician-reported outcomes, and our findings support its use in rheumatology practice.
